{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T22:18:51Z","timestamp":1794608331867,"version":"4.9.1"},"reference-count":0,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2003,10,29]],"date-time":"2003-10-29T00:00:00Z","timestamp":1067385600000},"content-version":"vor","delay-in-days":2249,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Endocrinology"],"published-print":{"date-parts":[[1997,9]]},"abstract":"<jats:sec><jats:title>OBJECTIVE<\/jats:title><jats:p>The optimum steroid hormone treatment regimes for transsexual subjects has not yet been established. We have investigated the mortality and morbidity figures in a large group of transsexual subjects receiving cross\u2010sex hormone treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>DESIGN<\/jats:title><jats:p>A retrospective, descriptive study in a university teaching hospital.<\/jats:p><\/jats:sec><jats:sec><jats:title>SUBJECTS<\/jats:title><jats:p>Eight hundred and sixteen male\u2010to\u2010female (M\u2003\u2003\u2192\u2003\u2003F) and 293 female\u2010to\u2010male (F\u2003\u2003\u2192\u2003\u2003M) transsexuals.<\/jats:p><\/jats:sec><jats:sec><jats:title>INTERVENTIONS<\/jats:title><jats:p>Subjects had been treated with cross\u2010sex hormones for a total of 10\u2003152 patient\u2010years.<\/jats:p><\/jats:sec><jats:sec><jats:title>OUTCOME MEASURES<\/jats:title><jats:p>Standardized mortality and incidence ratios were calculated from the general Dutch population (age\u2010 and gender\u2010adjusted) and were also compared to side effects of cross\u2010sex hormones in transsexuals reported in the literature.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>In both the M\u2003\u2003\u2192\u2003\u2003F and F\u2003\u2003\u2192\u2003\u2003M transsexuals, total mortality was not higher than in the general population and, largely, the observed mortality could not be related to hormone treatment. Venous thromboembolism was the major complication in M\u2003\u2003\u2192\u2003\u2003F transsexuals treated with oral oestrogens and anti\u2010androgens, but fewer cases were observed since the introduction of transdermal oestradiol in the treatment of transsexuals over 40 years of age. No cases of breast carcinoma but one case of prostatic carcinoma were encountered in our population. No serious morbidity was observed which could be related to androgen treatment in the F\u2003\u2003\u2192\u2003\u2003M transsexuals.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSION<\/jats:title><jats:p>Mortality in male\u2010to\u2010female and female\u2010to\u2010male transsexuals is not increased during cross\u2010sex hormone treatment. Transdermal oestradiol administration is recommended in male\u2010to\u2010female transsexuals, particularly in the population over 40 years in whom a high incidence of venous thromboembolism was observed with oral oestrogens. It seems that in view of the deep psychological needs of transsexuals to undergo sex reassignment, our treatment schedule of cross\u2010sex hormone administration is acceptably safe.<\/jats:p><\/jats:sec>","DOI":"10.1046\/j.1365-2265.1997.2601068.x","type":"journal-article","created":{"date-parts":[[2003,11,7]],"date-time":"2003-11-07T20:08:01Z","timestamp":1068235681000},"page":"337-343","source":"Crossref","is-referenced-by-count":435,"title":["Mortality and morbidity in transsexual subjects treated with cross\u2010sex hormones"],"prefix":"10.1111","volume":"47","author":[{"given":"Paul J. M.","family":"Van Kesteren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henk","family":"Asscheman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos A. J.","family":"Megens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis J. G.","family":"Gooren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2003,10,29]]},"container-title":["Clinical Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2265.1997.2601068.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2265.1997.2601068.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2265.1997.2601068.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T10:10:21Z","timestamp":1698401421000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2265.1997.2601068.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997,9]]},"references-count":0,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1997,9]]}},"alternative-id":["10.1046\/j.1365-2265.1997.2601068.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2265.1997.2601068.x","archive":["Portico"],"relation":{},"ISSN":["0300-0664","1365-2265"],"issn-type":[{"value":"0300-0664","type":"print"},{"value":"1365-2265","type":"electronic"}],"subject":[],"published":{"date-parts":[[1997,9]]}}}